BPC-157 · 5mg vial · research use only
BPC-157 half-life: short in plasma, longer in effect.
BPC-157's pharmacokinetics sit at the opposite end of the spectrum from a once-weekly peptide. Its systemic half-life is reported as very short — under about 30 minutes — yet the tissue-repair effects described in the literature persist well beyond that window. This page explains the short circulating half-life, why it drives daily and localized dosing, and the gap between plasma clearance and biological effect, as a research reference — not medical advice.
The number: under ~30 minutes
BPC-157's systemic (plasma) half-life is reported in the literature as very short — under roughly 30 minutes. The circulating peptide is cleared rapidly, which puts it in a completely different pharmacokinetic class from long-acting incretin peptides that persist for days. For any research model, the working assumption is that systemic exposure from a single administration is brief.
See the dosage reference →Why dosing is daily
A sub-30-minute half-life means there is no sustained plasma reservoir between doses, so research protocols model frequent administration — typically once daily, sometimes split twice daily — rather than the weekly cadence used for long-acting peptides. The dosing frequency is a direct consequence of how quickly the circulating peptide clears.
View the 5mg vial →The clearance / effect gap
The notable feature of BPC-157 is that its reported biological effects in tissue-repair models outlast its plasma presence by a wide margin. The peptide clears the bloodstream in minutes, yet the angiogenic and tissue-modelling effects described in the literature are observed over much longer windows — a sign the mechanism is not dependent on sustained circulating concentration.
BPC-157 research overview →Why localized delivery recurs
Because the systemic half-life is so short, the literature repeatedly explores near-site or localized delivery in tissue-repair research — keeping the peptide where it is studied to act rather than relying on a brief systemic pass. This is a recurring theme precisely because of the rapid plasma clearance, and it shapes how research models are designed.
The BPC-157 / TB-500 pairing →Half-life vs vial stability
The short half-life describes the compound's behaviour once in solution and circulating — it is unrelated to vial stability. Titan's lyophilized BPC-157 is stable at room temperature in transit and refrigerated long-term; once reconstituted with bacteriostatic water it has its own refrigerated shelf life. Half-life is a pharmacokinetic property, not a storage one.
Reconstitution & storage →Research-use framing
BPC-157 has no regulatory approval for human use and its pharmacokinetic data is largely preclinical. These figures are reproduced as a laboratory research reference for in-vitro and modelling work — not instructions for human use. Titan supplies BPC-157 strictly as a research reagent, and nothing here is medical or dosing advice.
Research-use policy →The detail, in plain terms
The pharmacokinetics, in one table.
BPC-157's short systemic half-life is what defines its dosing — frequent administration, localized delivery, and a clearance-versus-effect gap that sets it apart from long-acting peptides. These are the figures a research model actually uses.
- Compound
- BPC-157 — synthetic stable gastric pentadecapeptide (15 amino acids).
- Systemic half-life
- Very short — under ~30 minutes in plasma.
- Dosing cadence
- Typically daily (sometimes split) — no sustained plasma reservoir.
- Effect duration
- Reported tissue effects outlast plasma presence by a wide margin.
- Delivery note
- Localized / near-site delivery recurs in the literature.
- Format
- 5mg lyophilized vial, $54.99 — reconstitute before in-vitro use.
Questions researchers ask
Before you order.
- What is BPC-157's half-life?
- BPC-157's systemic (plasma) half-life is reported as very short — under roughly 30 minutes. The circulating peptide clears rapidly, placing it in a completely different pharmacokinetic class from long-acting peptides that persist for days. The figure is reproduced as a research reference, not medical advice.
- Why is BPC-157 dosed daily if the half-life is so short?
- Because there is no sustained plasma reservoir between doses, research protocols model frequent administration — usually daily, sometimes split twice daily — to maintain regular exposure. The dosing frequency follows directly from how quickly the circulating peptide clears.
- How can BPC-157 work if it clears in minutes?
- The reported biological effects in tissue-repair models outlast the peptide's plasma presence by a wide margin. BPC-157 clears the bloodstream within minutes, yet the angiogenic and tissue-modelling effects described in the literature are observed over much longer windows — suggesting the mechanism does not depend on sustained circulating concentration.
- Does the short half-life affect how BPC-157 is stored?
- No. Half-life describes how the compound behaves once in solution and circulating; it is unrelated to vial stability. Lyophilized BPC-157 is stable at room temperature in transit and refrigerated long-term, and once reconstituted with bacteriostatic water it has its own refrigerated shelf life.
- Is BPC-157 approved for human use?
- No. BPC-157 has no regulatory approval for human use and its pharmacokinetic data is largely preclinical. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.